Corvus Pharmaceuticals (CRVS) Stock Statistics & Valuation Metrics

Corvus Pharmaceuticals has a market cap or net worth of $559.37M. The enterprise value is $545.83M.

Corvus Pharmaceuticals has 74,681,870 shares outstanding. The number of shares has decreased by -2.65% in one year.

Corvus Pharmaceuticals’s return on equity (ROE) is -1.91 and return on invested capital (ROIC) is -81.77%.

The current PE Ratio of Corvus Pharmaceuticals is ―. Corvus Pharmaceuticals’s PEG ratio is -0.06.

In the last 12 months, Corvus Pharmaceuticals had revenue of 0.00 and earned -62.29M in profits. Earnings per share was -1.02.

In the last 12 months, operating cash flow was -32.07M and capital expenditures -149.00K, giving a free cash flow of -32.22M billion.

Corvus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Corvus Pharmaceuticals upcoming earnings date is Mar 5, 2026, TBA (Confirmed).

Corvus Pharmaceuticals as a current ratio of 1.54, with Debt / Equity ratio of 1.41%

In the past 12 months, Corvus Pharmaceuticals has paid 0.00 in taxes.

Corvus Pharmaceuticals EV to EBITDA ratio is -11.57, with an EV/FCF ratio of -12.53.

Corvus Pharmaceuticals has $65.69M in cash and marketable securities with $1.01M in debt, giving a net cash position of $64.68M billion.

Gross margin is -7.95%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Corvus Pharmaceuticals is $13.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy